5 active not recruiting. 5 Phase 2, 2 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 5 | Active not recruiting 5 |
| Phase 3 | 2 | Active not recruiting 2 |
Follow Hypopharyngeal Neoplasms: new trials by email Literature Review of Hypopharyngeal Neoplasms trials Research Report on Hypopharyngeal Neoplasms
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| INBRX-106 in Combination With Pembrolizumab in First-line PD-L1 CPS≥20 HNSCC INBRX-106, Pembrolizumab - Head and Neck Squamous Cell Carcinoma (HNSCC) | Phase 2 / Phase 3 | Active not recruiting | Inhibrx Biosciences, Inc | 410 | 2024-05-14 | 2026-05-08 |
| Testing the Use of Investigational Drugs Atezolizumab and/or Bevacizumab With or Without Standard Chemotherapy in the Second-Line Treatment of Advanced-Stage Head and Neck Cancers Atezolizumab, Bevacizumab, Biospecimen Collection - Clinical Stage IV HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Metastatic Head and Neck Squamous Cell Carcinoma | Phase 2 / Phase 3 | Active not recruiting | National Cancer Institute (NCI) | 430 | 2023-03-13 | 2026-10-01 |
| Testing the Addition of an Anti-cancer Drug, Ipatasertib, to the Usual Immunotherapy Treatment (Pembrolizumab) in Patients With Recurrent or Metastatic Squamous Cell Cancer of the Head and Neck Biopsy Procedure, Biospecimen Collection, Computed Tomography - Head and Neck Squamous Cell Carcinoma, Metastatic Head and Neck Squamous Cell Carcinoma | Phase 2 | Active not recruiting | National Cancer Institute (NCI) | 52 | 2022-07-26 | 2026-09-21 |
| Intensity Modulated Proton or X-Ray Therapy After Surgery for Treatment of Head and Neck Cancer, the HEADLIGHT Study Cisplatin, Intensity-Modulated Proton Therapy, Quality-of-Life Assessment - Head and Neck Carcinoma, Head and Neck Carcinoma of Unknown Primary | Phase 2 | Active not recruiting | Mayo Clinic | 174 | 2022-02-16 | 2026-07-16 |
| Cemiplimab, Low-Dose Paclitaxel and Carboplatin for the Treatment of Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck Carboplatin, Cemiplimab, Paclitaxel - Clinical Stage IV HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Metastatic Head and Neck Squamous Cell Carcinoma | Phase 2 | Active not recruiting | Marcelo Bonomi | 46 | 2021-11-30 | 2026-06-25 |
Laryngeal Neoplasms (5) · Mouth Neoplasms (5) · Oropharyngeal Neoplasms (4) · Squamous Cell Carcinoma of Head and Neck (4) · Carcinoma (2) · Head and Neck Neoplasms (1) · Lymphatic Metastasis (1) · Lymphoid Interstitial Pneumonia (1) · Nasopharyngeal Carcinoma (1) · Paranasal Sinus Neoplasms (1) · Salivary Gland Neoplasms (1)
Laryngeal Diseases (5) · Mouth Diseases (5) · Neoplasms (5) · Neoplasms by Site (5) · Otorhinolaryngologic Diseases (5) · Otorhinolaryngologic Neoplasms (5) · Pharyngeal Diseases (5) · Pharyngeal Neoplasms (5) · Respiratory Tract Diseases (5) · Respiratory Tract Neoplasms (5) · Stomatognathic Diseases (5) · Carcinoma, Squamous Cell (4) · Head and Neck Neoplasms (4) · Neoplasms by Histologic Type (4) · Neoplasms, Glandular and Epithelial (4)
Specimen Handling (3) · 1,2-diaminocyclohexaneplatinum II citrate (2) · Carboplatin (2) · Cisplatin (2) · Magnetic Resonance Spectroscopy (2) · Platinum (2) · pembrolizumab (2) · (225)Ac-DOTA-c(RGDyK) (1) · Bevacizumab (1) · Biopsy (1) · Cetuximab (1) · Disulfides (1) · Docetaxel (1) · Immunoglobulin G (1) · Paclitaxel (1)
National Cancer Institute (NCI) (2) · Inhibrx Biosciences, Inc (1) · Marcelo Bonomi (1) · Mayo Clinic (1)
United States (5) · Australia (1) · Belgium (1) · Bulgaria (1) · France (1) · Italy (1) · Malaysia (1) · Poland (1) · Romania (1) · South Korea (1) · Spain (1) · Taiwan (1) · United Kingdom (1)
Aarti Bhatia (1) · Jacob S Thomas (1) · Marcelo R Bonomi, MD (1) · Scott C. Lester, M.D. (1)
U10CA180820 (1), UM1CA186717 (1)